Lactobacillus Or Pediococcus Or Leuconostoc Patents (Class 424/93.45)
  • Patent number: 11903979
    Abstract: The present invention relates to compositions comprising Lactobacillus plantarum 2830 (ECGC 13110402), or mutant strain or strains thereof, for use in the treatment or prevention of hypertension.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: February 20, 2024
    Inventor: Stephen Patrick O'Hara
  • Patent number: 11857577
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: January 2, 2024
    Assignee: Labyrinth Holdings, LLC
    Inventor: Elizabeth McKenna
  • Patent number: 11813297
    Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 14, 2023
    Assignees: Katholieke Universiteit Leuven, KU Leuven R & D, Universiteit Antwerpen
    Inventors: Camille Allonsius, Ilke De Boeck, Stijn Wittouck, Sander Wuyts, Sarah Lebeer, Peter Hellings
  • Patent number: 11801274
    Abstract: Disclosed herein is a method for alleviating atopic dermatitis using a composition containing at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the CCTCC under an accession number CCTCC M 2014588.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: October 31, 2023
    Assignee: GLAC BIOTECH CO., LTD.
    Inventors: Hsieh-Hsun Ho, Yi-Wei Kuo, Yen-Yu Huang, Jia-Hung Lin, Ko-Chiang Hsia, Ching-Wei Chen, Shin-Yu Tsai
  • Patent number: 11779614
    Abstract: The present invention relates to compositions comprising galactooligosaccharides (GOS) and probiotic bacteria obtained by a process comprising the step of growing the bacteria in a medium comprising GOS, such composition having the effect of boosting the synbiotic effect of the probiotic bacteria with the GOS. Health benefits of the probiotic bacteria as obtained by such a fermentation process are also contemplated.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: October 10, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Biljana Bogicevic, Jeroen Andre Muller, Nicolas Page, Guenolee Eliane Marie Prioult, Wilbert Sybesma, Thomas Sasse, Benoit Marsaux
  • Patent number: 11766050
    Abstract: The present invention is a yogurt product that may be consumed by dogs and other mammalian pets. The yogurt product is in an unflavored form comprising as essential constituents: (A) 0% to 88% by weight water; (B) 0.2% to 25% by weight of a no-fat protein component selected from the group consisting of skim milk and cultured skim milk; (C1) 0.001% to 6% by weight sugar component comprising: (C1) 0.001% to 6% polydextrose and (C2) 0.001% to 6% Glycoses and Galactoses; (D) 2% to 8% by weight milk derived solids; (E) 0.2% to 2.5% by weight stabilizers and emulsifiers; and (F) at least one probiotic microorganism. The yogurt product may be refrigerated and served as a mousse, frozen dessert, or as a fermented yogurt drink similar to Ayran or Kefir. A method for producing the yogurt product is also disclosed herein.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: September 26, 2023
    Assignee: COUNTRY FOOD, LLC
    Inventor: Mesut Baysal
  • Patent number: 11752180
    Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: September 12, 2023
    Assignees: National University Corporation Asahikawa Medical University, Sapporo Holdings Limited
    Inventors: Yutaka Kohgo, Mikihiro Fujiya, Nobuhiro Ueno, Syuichi Segawa, Naoyuki Kobayashi
  • Patent number: 11730776
    Abstract: Provided is a novel prophylactic and/or therapeutic agent for Clostridium difficile infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and/or treat Clostridium difficile infection. The prophylactic and/or therapeutic agent for Clostridium difficile infection, comprising a bacterium belonging to the genus Enterococcus. A medicine for prevention and/or treatment of Clostridium difficile infection, comprising a bacterium belonging to the genus Enterococcus. A food for prevention and/or treatment of Clostridium difficile infection, comprising a bacterium belonging to the genus Enterococcus.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 22, 2023
    Assignee: NUTRI CO., LTD.
    Inventors: Susumu Kawaguchi, Miho Kato
  • Patent number: 11628193
    Abstract: The present invention relates to selected strains of lactic bacteria for use in the treatment of infections caused by pathogenic bacteria belonging to the species Propionibacterium acnes, in particular for use in the preventive and/or curative treatment of dermatitis in general, seborrheic dermatitis, rosacea, eczema and acne. In addition, the present invention relates to a composition which comprises a mixture comprising or, alternatively, consisting of selected strains of lactic bacteria for use in the treatment of infections caused by pathogenic bacteria belonging to the species Propionibacterium acnes, in particular for use in the preventive and/or curative treatment of dermatitis in general, seborrheic dermatitis, rosacea, eczema and acne.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: April 18, 2023
    Assignee: PROBIOTICAL S.P.A.
    Inventor: Giovanni Mogna
  • Patent number: 11622981
    Abstract: Provided is a composition comprising an isolated Lactobacillus paracasei D3.5 strain or cellular components thereof. In some embodiments, the composition is provided in a pharmaceutically acceptable carrier, which may be a food product, tablet or capsule suitable for enteral administration, etc. Also provided is a composition comprising lipoteichoic acid isolated from Lactobacillus paracasei D3.5 strain, which may be provided in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: April 11, 2023
    Assignee: Wake Forest University Health Sciences
    Inventors: Hariom Yadav, Shaohua Wang, Ravinder Nagpal
  • Patent number: 11612171
    Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 28, 2023
    Assignee: GLAC BIOTECH CO., LTD.
    Inventors: Pei-Shan Hsieh, Chung-Wei Kuo, Yi-Chun Tsai, Hsieh-Hsun Ho, Yi Wei Kuo
  • Patent number: 11602552
    Abstract: The present invention relates to a composition comprising at least one selected from the group consisting of a novel lactic acid bacterium, Lactobacillus plantarum KBL396 (KCTC13278BP), culture of the strain, lysate of the strain and extract of the strain, and its use for food and medicine. The strain and composition according to the present invention has an excellent effect on improvement of neurological diseases, particularly improvement of mental disorders and neurodegenerative diseases, and has no risk of side effects in a human body, and thus it can be usefully utilized as a use for improvement of neurological diseases.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 14, 2023
    Assignee: KOBIOLABS, INC.
    Inventors: Yongbin Choi, Jisoo Kim, June-Chui Lee, Gwang Pyo Ko, Tae-Wook Nam, Jun-Hyeong Kim, Bo-Ram Cho
  • Patent number: 11564954
    Abstract: The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with decoy polypeptides that bind endogenous ligand and block activation of signal transduction cascades associated with cancer cell proliferation and tumor growth. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: January 31, 2023
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Wei Kong, Lingchen Fu, Yixin Shi
  • Patent number: 11517579
    Abstract: This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 6, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Clara Lucia Garcia-Rodenas, Jose Manuel Ramos Nieves, Myriam Sandrine Steinmann
  • Patent number: 11491196
    Abstract: The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: November 8, 2022
    Assignees: Universiteit Gent, Microbial Resource Management Health NV MRM Health
    Inventors: Sam Possemiers, Massimo Marzorati, Tom Van de Wiele, Ilse Scheirlinck, Pieter Van den Abeele, Selin Bolca, Davide Gottardi
  • Patent number: 11490631
    Abstract: An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and/or casein, a galactomannan thickener, and a fermented milk-derived product.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignee: N.V. NUTRICIA
    Inventors: Marie Thomas, Francis Lecroix, Evan Abrahamse, Houkje Bouritius
  • Patent number: 11478515
    Abstract: The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: October 25, 2022
    Assignee: GLAXOSMITHKLINE CONSUMER HEALTHCARE S.R.L.
    Inventors: Valeria Longoni, Marisa Penci
  • Patent number: 11464821
    Abstract: The present invention relates to a composition for preventing and treating cancer-related fatigue, characterized by containing a new processed ginseng powder or a new processed ginseng extract having an increased amount of a ginsenoside constituent, which was previously minute, by preparing a saponin-decomposing enzyme and subsequently using hydrolysis by the prepared saponin-decomposing enzyme and an organic acid. The composition according to the present invention can be very effectively used for preventing and treating cancer-related fatigue, the most destructive and universal side effect, which is caused by cancer itself or occurs in association with the treatment of cancer.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 11, 2022
    Assignee: GREEN CROSS WELLBEING CORPORATION
    Inventors: Young Hyo Yoo, Jeom Yong Kim, Joo Young Kim, Sun Kyu Park
  • Patent number: 11446340
    Abstract: Selection of probiotic strains belonging to the genus Bifidobacterium and to a symbiotic composition containing the same for use of feeding infants, is described.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 20, 2022
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
  • Patent number: 11439672
    Abstract: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Ganeden Biotech, Inc.
    Inventors: Sean Farmer, Andrew R. Lefkowitz
  • Patent number: 11419882
    Abstract: The present disclosure provides a composition comprising a first amount of a Vitamin D compound and a second amount of a probiotic compound. The disclosure also provides a method of treating an atopic condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition detailed herein.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: August 23, 2022
    Inventors: Robert McDermott, Neal Jain
  • Patent number: 11419885
    Abstract: A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: August 23, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Norbert Sprenger, Clemens Kunz, Dominique Brassart
  • Patent number: 11400124
    Abstract: The present invention relates to the use of probiotics, preferably one or more probiotic bacteria, to increase the absorption of proteins or the bioavailability thereof, preferably in individuals with increased protein and/or energy requirements, preferably elderly persons, children, pregnant women or athletes.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: August 2, 2022
    Assignee: SOFAR S.P.A.
    Inventor: Andrea Biffi
  • Patent number: 11395839
    Abstract: The present invention provides methods of treating or preventing gestational diabetes by administering Lactobacillus rhamnosus HN001 or derivatives thereof, in addition to uses, compositions, and medicaments comprising Lactobacillus rhamnosus HN001 or derivatives thereof to treat or prevent gestational diabetes mellitus.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 26, 2022
    Assignee: University of Otago
    Inventor: Kristin Lee Wickens
  • Patent number: 11389492
    Abstract: The invention pertains to the use of a probiotic and a beta-lactoglobulin-derived peptide in the manufacture of a product for use in inducing oral tolerance, and/or treatment, prevention or reducing the risk of allergy in a subject, in particular cow's milk protein allergy.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 19, 2022
    Assignee: N.V. NUTRICIA
    Inventors: Leon Matthieu Johannes Knippels, Johan Garssen
  • Patent number: 11382940
    Abstract: The present invention relates to Lactobacillus salivarius CJLS1511, a composition for animal feed additives comprising the same or its inactivated bacterial cells, and a method for preparing the inactivated bacterial cells.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: July 12, 2022
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Ji Eun Kim, Kyeong Su Chae, Sung Hun Kim, Seok Woo Chee, Joong Su Lee
  • Patent number: 11369646
    Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: June 28, 2022
    Assignee: BIOGAIA AB
    Inventors: Clara Lucia Garcia-Rodenas, Bernard Berger, Catherine Ngom-Bru, Melissa Lepage, Tara Neville
  • Patent number: 11364269
    Abstract: The disclosure relates to a therapeutic composition for treating L. monocytogenes infection or L. monocytogenes colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 21, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Simone Becattini, Eric Pamer, Sohn Kim
  • Patent number: 11324236
    Abstract: The present invention provides a productivity enhancing agent, a wasting rate-reducing agent, an ameliorating agent for ascites, emaciation, or maldevelopment, and a prophylactic or therapeutic agent for inflammation or colibacillosis for use in poultry such as chickens for meat, which comprises unheated cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 10, 2022
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Yuji Shizuno, Chie Hikita, Yasuhiro Suzuki
  • Patent number: 11318181
    Abstract: The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gut-mucosa.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 3, 2022
    Assignee: PROBI AB
    Inventors: Camilla Bränning, Margareta Nyman
  • Patent number: 11285180
    Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: March 29, 2022
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Université Paul Sabatier Toulouse III
    Inventors: Remy Burcelin, Francois Terce, Estelle Grasset, Jeffrey Christensen, Xavier Collet
  • Patent number: 11273188
    Abstract: Provided are gut microbes or cultures having anti-obesity efficacy and a pharmaceutical composition containing them. The gut microbes or cultures have anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in a mammalian gastrointestinal tract for the prevention and treatment of obesity and obesity related diseases. This invention demonstrated that said gut microbes having anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in the gastrointestinal tract of mammals have the anti-obesity efficacy as much as that of the representative anti-obesity drug, orlistat, without any side effects in animal experiments and clinical trials. Therefore, the gut microbes h can be used to develop universal anti-obesity drugs for obese patients, contributing greatly to the health of mankind.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 15, 2022
    Assignee: MICROBIOTICA GMBH
    Inventors: Hyeon Jin Kim, Seong Tshool Hong, Jae Gak Yu
  • Patent number: 11260087
    Abstract: Provided is a novel Lactobacillus acidophilus YTI strain (deposition number: KCCM 11808P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus acidophilus comprising the novel strain.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 1, 2022
    Assignee: KOREA FOOD RESEARCH INSTITUTE
    Inventors: Young-Do Nam, Yun-Tai Kim, Hee Soon Shin, So-Young Lee, Jae-Goo Kim, Eun-Yeong Lim, Eun-Ji Song
  • Patent number: 11235060
    Abstract: The invention relates to compositions for vaginal or, alternatively, oral administration and to the use of such compositions for stabilizing the vaginal, or, alternatively, the intestinal acidity and establishing favorable conditions for the inhibition of pathogens and the growth of lactobacilli in the urogenital, or, alternatively, gastro-intestinal tract.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: February 1, 2022
    Assignee: PROBIOSWISS AG
    Inventor: Federico Graf
  • Patent number: 11224651
    Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, for use in preventing and/or treating allergy symptoms in an infant or a young child, by increasing propionate production, in said infant or young children.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 18, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Carine Blanchard, Chiara Nembrini
  • Patent number: 11213559
    Abstract: The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: January 4, 2022
    Assignee: ABOCA S.P.A. SOCIETÀ AGRICOLA
    Inventors: Valentino Mercati, Anna Maidecchi, Laura Capone
  • Patent number: 11213055
    Abstract: The present inventors disclose new fermentate compositions that display antimicrobial activity against a variety of microorganisms in foods. The fermentate compositions may not only be active at acidic pHs, but also retain antimicrobial activity at elevated pHs including neutral pHs. In addition to new fermentate compositions, the present invention also relates to improved methods for making such fermentate compositions and using unpurified fermentate compositions to effectively preserve food products.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: January 4, 2022
    Assignee: Third Wave Bioactives, LLC
    Inventors: Shelly Gebert, Matthew Hundt
  • Patent number: 11207359
    Abstract: The present invention provides a cholesterol reducing probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum TCI507, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: December 28, 2021
    Assignee: TCI CO., LTD.
    Inventor: Yung-Hsiang Lin
  • Patent number: 11207360
    Abstract: A pharmaceutical composition comprising at least a probiotic and at least a carotene, for the treatment of dysbiosis of the intestinal microbiota, is disclosed. The association of these ingredients allowed to obtain a clear synergistic effect.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: December 28, 2021
    Assignee: NUTRAVIS S.R.L.
    Inventors: Mirko Magnone, Elena Zocchi
  • Patent number: 11202811
    Abstract: The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activities such as antioxidant activity, ?-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity or tight junction protein expression-inducing activity. Accordingly, a certain Lactobacillus sp. strain, certain Bifidobacterium sp. strain or mixture thereof according to the present invention may be used as a functional food or medicinal material useful for the prevention, alleviation or treatment of intestinal damage, liver injury, allergic disease, inflammatory disease, or obesity.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 21, 2021
    Inventors: Dong Hyun Kim, Myung Joo Han
  • Patent number: 11185563
    Abstract: The present invention discloses uses of treating, preventing or improving bone diseases by Lactobacillus or a composition including the Lactobacillus. The Lactobacillus and compositions can increase the blood calcium concentration, the trabecular bone volume density, the trabecular thickness, the trabecular number and the bone mineral density of a subject, and reduce trabecular spacing of the subject. Further, the present invention discloses a method for treating a subject diagnosed with a bone disease, through identifying the subject having the bone disease and administering to the subject an effective amount of a composition including at least one of Lactobacillus plantarum GKM3 and Lactobacillus paracasei GKS6, wherein the Lactobacillus plantarum GKM3 is deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on Aug. 25, 2017, and the Lactobacillus paracasei GKS6 is deposited in CGMCC with a deposition number of CGMCC 14566 on Aug. 25, 2017.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 30, 2021
    Assignee: GRAPE KING BIO Ltd.
    Inventors: Chin-Chu Chen, Yen-Lien Chen, Shin-Wei Lin, Yen-Po Chen, Yang-Tzu Shih, Ching-Wen Lin
  • Patent number: 11160825
    Abstract: This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to treat fatty liver disease.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 2, 2021
    Assignee: Research Foundation of the State University of New York
    Inventors: George B. Stefano, Richard Kream, Kirk J Mantione
  • Patent number: 11135232
    Abstract: The invention discloses a composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising from 40 to 80 wt % of fucosylated oligosaccharide(s), from 10 to 50 wt % of N-acetylated oligosaccharide(s), from 5 to 40 wt % of sialylated oligosaccharide(s) and from 0 to 20 wt % of precursor(s) of human milk oligosaccharide, for use in preventing and/or in treating necrotizing enterocolitis in infants and young children.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 5, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventor: Per Torp Sangild
  • Patent number: 11123385
    Abstract: Provided are a functional food or pharmaceutical composition or a method for preventing, alleviating or treating hyperphosphatemia and chronic kidney disease and treating chronic kidney disease using the composition comprising Lactobacillus sp. KCCM 11826P having excellent phosphorus-absorbing ability.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: September 21, 2021
    Assignees: Korea Food Research Institute, Catholic Kwandong University Industry Foundation
    Inventors: Hyo Jin Kim, Hae Won Jang, Young-Wook Chin, Woo Kyung Kang, Sung Jin Moon
  • Patent number: 11103157
    Abstract: Systems and methods have been developed for implementation of a portable SIBO testing system for convenient sampling of intestinal gases exhaled from a patient's breath. These devices may be in the form of a hand held meter that would integrate with a smartphone or other device with an application that can record data relating to food consumed by a user. Various technologies may be utilized to measure the levels of gases exhaled by a user, which may include (1) sorbent based technology and (2) membrane based technology. In some examples, the system will determine an indication of whether a patient has SIBO by adjusting a change in exhaled hydrogen concentration by a methane level exhaled by a patient.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: August 31, 2021
    Inventors: Kapil Gupta, Mark Pimentel, Ali Rezaie
  • Patent number: 11096410
    Abstract: The invention discloses a composition comprising oligosaccharide, for use in the prevention and/or treatment of skin conditions and/or skin diseases by increasing SCFA, in particular colonic propionate and butyrate. Said skin disease is in particular atopic dermatitis.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: August 24, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Carine Blanchard, Chiara Nembrini
  • Patent number: 11096948
    Abstract: Composition and methods suitable for treating Helicobacter infection and diseases associated therewith are provided. The composition containing fusidic acid or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: August 24, 2021
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventor: Dan Oren
  • Patent number: 11090357
    Abstract: The present application relates to an animal feed supplement for improving animal health and meat production compromising Next Generation Bioengineered Probiotics (NGBP). In some embodiments, the present application relates to a method for treating or preventing an inflammatory condition of a patient comprising the step of administering a therapeutically effective amount of Generation Bioengineered Probiotics (NGBP), together with one or more pharmaceutically acceptable carriers, diluents, and excipients, to the patient in need of relief from said inflammatory condition. In some other embodiments, the present invention relates to method for improving animal health and/or meat production comprising the step of adding an effective amount of Next Generation Bioengineered Probiotics (NGBP) to the feed of said animal.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: August 17, 2021
    Assignee: Purdue Research Foundation
    Inventors: Arun K Bhunia, Rishi Drolia, Ok Kyung Koo, Mary Anne Amalaradjou
  • Patent number: 11065200
    Abstract: The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 20, 2021
    Assignee: MENDES S.R.L.
    Inventor: Seok-Jin Kim
  • Patent number: 11053474
    Abstract: The invention concerns novel Lactobacillus strains and the uses thereof, in particular for preserving foods, animal feedstuff, pharmaceutical compositions and/or cosmetic compositions.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 6, 2021
    Assignee: Novozymes A/S
    Inventors: Detlef Goelling, Andreas Heilmann, Christine Lang